Brief: Reg-Galapagos Initiates Phase 3 Program With Filgotinib In Patients With Active Axial Spondyloarthritis
26/04/2023 21:01
April 26 (Reuters) - Galapagos NV GLPG.AS :
* REG-GALAPAGOS INITIATES PHASE 3 PROGRAM WITH FILGOTINIB IN
PATIENTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS
Source text for Eikon: ID:nGNEhlmNW
Further company coverage: GLPG.AS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lakefront Biotherapeutics NV
See all newsBrief: Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline
Brief: Lakefront Receives Transparency Notification From Bank Of America
Belgium's Galapagos Q1 revenue falls 91% but returns to profit
Brief: Galapagos, Gilead Enter Binding Agreement On Ouro Medicines Acquisition
Brief: Galapagos Announces Nomination Of Gino Santini To Its Board Of Directors